ALSO NOTED: FDA deadline looms for Trexima; Manhattan Pharma discontinues program; and much more...

> An August 1 FDA action date for Pozen's migraine drug Trexima is looming, and the analysts are paying close attention as the decision deadline nears. Report

> Manhattan Pharmaceuticals says it will discontinue its Oleoyl-estrone program for obesity after seeing disappointing Phase IIa data. Release

> Theravance says its mid-stage study of the antibiotic TD-1792 met its primary endpoint of noninferiority to vancomycin. Release

> Germany's MediGene grabbed the headlines at a conference in Switzerland recently with new efficacy data from a Phase I/II trial of a genetically engineered herpes virus designed to kill cancer cells. Report

> Aveo Pharmaceuticals says it's developed a better mouse model for cancer tumors that will give it a big advantage in the race to develop new cancer therapies. But Aveo says this is one advance that they intend to keep in-house for use solely with their own discovery programs. Report

> The amazingly hot field of synthetic biology has now spawned an engineered virus that attacks bacteria. Report

And Finally… Despite company losses, Maryland CEOs are enjoying a big payday. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.